Volume 1.43 | Nov 12

Prostate Cell News 1.43, November 12, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe

TOP STORY

Researchers ID Potential Target for Therapy in Patients with Deadly Type of Prostate Cancer
A monoclonal antibody targeting a well-known cell-surface protein inhibited the growth and spread of prostate cancer in an aggressive form of the disease that did not respond to hormone therapy, according to a study. [Press release from the University of California, Los Angeles discussing online prepublication in Nature Medicine]

ALDEFLUORCSC_645x110



SPECIAL FEATURE

Interested in recruiting talented individuals? Post your career opportunities in Prostate Cell News at no cost. Contact us at [email protected]

Follow us on Twitter! @ProstateCell



SCIENCE NEWS

Soy May Stop Prostate Cancer Spread
Researchers have found that a new, nontoxic drug made from a chemical in soy could prevent the movement of cancer cells from the prostate to the rest of the body. [Press release from Northwestern University Feinberg School of Medicine discussing research presented at the Ninth Annual American Association for Cancer Research Frontiers in Cancer Prevention Research Conference]

New Link Between Growth Factors and Early Prostate Cancer Found
A new study has found potential new biomarkers for very early prostate cancer in men with no symptoms of the disease. [Press release from the University of Bristol discussing research presented at the National Cancer Research Institute Cancer Conference]

Colorectal Cancer Risk Increases in Prostate Cancer Patients on Androgen Deprivation Therapy
Men taking androgen deprivation therapy for prostate cancer may have an increased risk of colorectal cancer, according to a study. [Press release from EurekAlert! discussing online prepublication in the Journal of the National Cancer Institute]

Watch Procedure Now  
Optimized Enzymes and Protocols for
Prostate Tissue Dissociation

by STEMCELL Technologies
 
 
CLICK HERE TO LEARN MORE STEMCELL Technologies Inc
 



LABORATORY RESEARCH

Monoclonal Antibody Targeting of N-Cadherin Inhibits Prostate Cancer Growth, Metastasis and Castration Resistance
Comparing gene expression in isogenic androgen-dependent and castration-resistant prostate cancer (CRPC) xenografts, researchers found a reproducible increase in N-cadherin expression, which was also elevated in primary and metastatic tumors of individuals with CRPC. [Nat Med]

Insulin-Like Growth Factor I Suppresses Bone Morphogenetic Protein Signaling in Prostate Cancer Cells by Activating mTOR Signaling
Insulin-like growth factor (IGF) I and bone morphogenetic proteins (BMP) are critical regulators of prostate tumor cell growth. In this report, researchers offer evidence that a critical support of IGF-I in prostate cancer is mediated by its ability to suppress BMP4-induced apoptosis and Smad-mediated gene expression. [Cancer Res]

Opposite Functions of HIF-Alpha Isoforms in VEGF Induction by TGF-Beta1 Under Non-Hypoxic Conditions
Researchers demonstrate here that tumor-producing transforming growth factor (TGF)-beta1 induces vascular endothelial growth factor (VEGF) in prostate cancer cells, and hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha has opposite functions in TGF-beta1 regulation of VEGF expression under non-hypoxic conditions. [Oncogene]

The Bcl-2-Beclin 1 Interaction in (-)-Gossypol-Induced Autophagy Versus Apoptosis in Prostate Cancer Cells
The results provide new insights into the mode of cell death induced by Bcl-2 inhibitors, which could facilitate the rational design of clinical trials by selecting patients who are most likely to benefit from the Bcl-2-targeted molecular therapy. [Autophagy]

Ligation of Prostate Cancer Cell Surface GRP78 Activates a Pro-Proliferative and Anti-Apoptotic Feedback Loop: A Role for Secreted PSA
In the current study, researchers demonstrate that ligation of prostate cancer cell surface GRP78 by its natural ligand, activated alpha2-macroglobulin (alpha2M*), results in a two-threefold upregulation in the synthesis of prostate specific antigen (PSA). [J Biol Chem]

Recurrence-Free Survival in Prostate Cancer is Related to Increased Stromal TRAIL Expression
TRAIL (tumor necrosis factor related apoptosis-inducing ligand) is involved in tumor immune surveillance and, thus, may be a potential cancer therapy. TRAIL expression in the tumor microenvironment has been shown to impact cancer survival in multiple tumor types, including ovarian cancer. Researchers studied TRAIL expression and outcomes in patients with prostate cancer. [Cancer]

CLINICAL RESEARCH

Risk of Colorectal Cancer in Men on Long-Term Androgen Deprivation Therapy for Prostate Cancer
Long-term androgen deprivation therapy for prostate cancer is associated with an increased risk of colorectal cancer. [J Natl Cancer Inst]

Ten-Year Outcomes of High-Dose, Intensity-Modulated Radiotherapy for Localized Prostate Cancer
The authors investigated long-term tumor control and toxicity outcomes after high-dose, intensity-modulated radiation therapy in patients who had clinically localized prostate cancer. [Cancer]

Prostate Cancer at the Peripheral End of a Prostate Biopsy Specimen as Assessed by a Novel Marking Technique May Indicate Increased Risk of Locally Advanced Disease
The objective of this study was to test a novel technique of processing a prostate biopsy specimen by marking its peripheral end as a predictive tool for locally advanced prostate cancer or margin-positive resection after radical prostatectomy. [Prostate Cancer Prostatic Dis]



INDUSTRY NEWS

SuperGen Discontinues Clinical Development of SGI-1776
SuperGen, Inc. announced that it has discontinued clinical development of its phase I PIM kinase drug candidate, SGI-1776, while continuing development of the PIM inhibitor program. [SuperGen, Inc. Press Release]

Adamis Completes $10 Million Common Stock Purchase Agreement
Adamis Pharmaceuticals Corporation announced the signing of a definitive common stock purchase agreement with Eses Holdings Limited, a company located in the United Arab Emirates. [MarketWire]

MabCure Generates Tumor Specific Antibodies Against Prostate Cancer Which Could Lead to a Blood/Urine Diagnostic Test for Prostate Cancer
Biotechnology company MabCure, Inc. announced that it has generated a panel of 10 novel monoclonal antibodies (MAbs) against prostate cancer. These MAbs were selected from more than 30,000 MAbs produced by MabCure’s proprietary technology. [BusinessWire]

Bavarian Nordic Says Seeks Cancer Vaccine Partner
Danish biopharma group Bavarian Nordic reported deepening nine-month losses and said it was in advanced talks with potential partners for its Prostvac prostate cancer vaccine. [Reuters]





EVENTS (Listed by Date)

22nd European Organization for Research and Treatment of Cancer (EORTC)-National Cancer Institute (NCI)-American Association for Cancer Research (AACR) Symposium: Molecular Targets and Cancer Therapeutics
November 16-19, 2010
Berlin, Germany

Cancer Pharmacogenetics: Personalizing Medicine
November 22-24, 2010
Madrid, Spain

American Association for Cancer Research (AACR) Tumor Immunology – Basic and Clinical Advances
November 30-December 3, 2010
Miami, United States

5th Annual Stem Cell Meeting on the Mesa
December 7, 2010
La Jolla, United States

11th Annual Meeting of the Society of Urologic Oncology (SUO): Extraordinary Opportunities for Discovery
December 8-9, 2010
Bethesda, United States

NEW The 3rd Guangzhou International Conference on Stem Cell Biology and Regenerative Medicine
December 17-19, 2010
Guangzhou, China

American Association for Cancer Research (AACR) Targeting PI3K/mTOR Signaling in Cancer
February 24-27, 2011
San Francisco, United States

American Association for Cancer Research (AACR) Stem Cells, Development, and Cancer
March 3-6, 2011
Vancouver, Canada

MENA Oncology Conference
March 11-12, 2011
Cairo, Egypt

The 6th International Conference on Oncolytic Viruses as Cancer Therapeutics
March 16-19, 2011
Las Vegas, United States

United Kingdom National Stem Cell Network 2011 Annual Scientific Conference
March 30-April 1, 2011
York, United Kingdom

American Association for Cancer Research (AACR) 102nd Annual Meeting 2011
April 2-6, 2011
Orlando, United States

International Society for Stem Cell Research (ISSCR) 9th Annual Meeting
June 15-18, 2011
Toronto, Canada

National Cancer Institute (NCI) Cancer Research Imaging Camp
June 19-24, 2011
St. Louis, United States

4th Annual Advances in Biodetection & Biosensors Conference and Exhibition
June 30-July 1, 2011
Hamburg, Germany

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


JOB OPPORTUNITIES


Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies)

Lab Technologist – Tissue Culture (STEMCELL Technologies)


Product Manager – Pluripotent Stem Cells (STEMCELL Technologies)

Business Manager – Centre for Blood Cell Therapies (Cell Therapies)


Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Prostate Cell News at no cost.
Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.


Learn more about Prostate Cell News: Archives  |  Events  |  Subscribe  |  Contact Us